Lot-to-lot consistency, immunogenicity, and safety of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy adults: A randomized, double-blind, phase IV trial

Lot-to-lot consistency, immunogenicity, and safety of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy adults: A randomized, double-blind, phase IV trial

Previous phase I to III clinical trials have shown that the inactivated SARS-CoV-2 vaccine namely CoronaVac has good efficacy, safety, and immunogenicity. This phase IV trial aims to evaluate the lot-to-lot consistency, immunogenicity, and safety on a commercial scale in healthy adults, which could...

Full description

Bibliographic Details
Main Authors: Dandan Zhu, Yuansheng Hu, Zhiwei Jiang, Tuantuan Yang, Kai Chu, Hengming Zhang, Jialei Hu, Xing Meng, Zhijun Tan, Jingliang Wu, Xiaojuan Lian, Changgui Li, Hongxing Pan
Format: Article
Language:English
Published: Taylor & Francis Group 2022-11-01
Series:Human Vaccines & Immunotherapeutics
Subjects:
lot-to-lot consistency
immunogenicity
safety
sars-cov-2
coronavac
Online Access:http://dx.doi.org/10.1080/21645515.2022.2135929

Internet

http://dx.doi.org/10.1080/21645515.2022.2135929

Similar Items